Sun and Incyte 解决了一起诉讼 允许Sun在美国出售 头发重新生长的药物 Leqselvi Sun and Incyte settled a lawsuit, allowing Sun to sell the hair regrowth drug Leqselvi in the U.S.

Sun制药业和Incyte公司解决了对Alopecia esata药物Leqselvi的诉讼。 Sun Pharmaceutical Industries and Incyte Corporation settled a lawsuit over the alopecia areata drug Leqselvi. 作为和解的一部分,Incyte向Sun颁发了在非癌症条件下使用该药物的有限许可证,允许Sun在美国临床试验中发射Leqselvi。 结果表明,三分之一的病人在第24周前恢复了大部分头发。 As part of the settlement, Incyte granted Sun a limited license for the drug's use in non-cancer conditions, allowing Sun to launch Leqselvi in the U.S. Clinical trials showed that one-third of patients regained most of their hair by Week 24. 预计到2030年,该药物的销售额将高达4亿美元。 The drug is projected to generate up to $400 million in sales by 2030.